Emmaus Life Sciences, Inc. (OTCPK: EMMA)
Health Care · Pharmaceuticals · US
$0.03
+179.13% today · +172.0% 1Y
Emmaus Life Sciences, Inc. (OTCPK: EMMA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.25M and employs 33 people.
Over the last twelve months the share price has gained 172.0%, trading between 0.01 and 0.04.
Tweenvest scores Emmaus Life Sciences, Inc. across four factors: quality 30/100, value 56/100, growth 0/100. Its strongest factor is value.
EMMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.25M
- Revenue (TTM)
- $15.53M
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 9.68
- 52-week high
- $0.04
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 70.19M
- Employees
- 33
- Next earnings
- —
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
- ISIN
- US29137T1016
- Founded
- 2000
- Listed since
- May 9, 2000
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,195.00 | -3.13% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.33 | -1.03% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.44 | -1.92% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.39 | -0.65% |
Figures last refreshed Aug 18, 2026.